Listen Now

In this podcast, Dr. Milagros Samaniego describes new molecular targets for inhibiting antibody production by plasma cells and their precursor B cells. She also discusses the potential role for complement inhibitors such as ecalizumab for the treatment of antibody-mediated rejection. In addition, she discusses the mechanisms of action of proteosome inhibitors and their potential clinical role in treating humoral rejection and in desensitization protocols.